Upexi (UPXI) Regains Nasdaq Compliance

Filing Form 10-K for the Year Ended June 30, 2024

Filing Form 10-Q for the Quarter Ending September 30, 2024

Upexi, Inc. (NASDAQ: UPXI) announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic reports that the Company now complies with the Rule and accordingly these matters are now closed.

Allan Marshall, Chief Executive Officer of Upexi, stated, "We are pleased to have filed our financial results for the fiscal year ending June 30, 2024 and fiscal first quarter ending September 30, 2024. During this period, we completed several critical transactions as part of our restructuring process, which has resulted in a significant reduction in debt and increase in working capital. We have sufficient working capital to fund our operations meet our debt obligations. Going forward, we have stable and cash flowing manufacturing, distribution and fulfillment facilities in Florida as well as a portfolio of pet, health and CBD brands. We have completed the restructuring and can focus on operating our businesses and explore new opportunities for the future."

Operational Highlights:

• Successfully sold its equity interest in Interactive Offers, LLC, VitaMedica, and E-Core Technology, Inc.

• Completed sale of building.

• Upexi continues to operate its manufacturing and distribution centers in Odessa, Florida and warehousing, distribution and other services for product sales in Tampa, Florida.

• These facilities include operations by Gumi Labs, which manufactures gummies and other products, including products manufactured with hemp ingredients.

• The manufacturing facilities in Florida are operating at full capacity as of August of 2024.

• Upexi also continues to market and distribute its LuckyTail, PRAX, Cure Mushrooms, and Moonwlkr brands.

You May Also Be Interested In

• U.S. debt tops $40 trillion
• John B. Sanfilippo & Son (JBSS) Misses Q4 EPS by 59c
• Encompass Health Corporation (EHC) files mixed shelf